BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

Dermatitis, pneumonia vaccine data for Pfizer  Pfizer Inc. (NYSE:PFE) reported Phase III data for atopic dermatitis therapy abrocitinib and pneumococcal vaccine 20vPnC Wednesday. The JAK-1 inhibitor met the co-primary efficacy endpoints vs. placebo in the...
BC Week In Review | Apr 19, 2019
Clinical News

Pfizer's 20-valent pneumonia vaccine safe, immunogenic in Phase II

Pfizer said its pneumococcal conjugate vaccine 20vPnC (PF-06482077) was safe and led to "robust" immunogenicity in a Phase II trial to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the product....
Items per page:
1 - 2 of 2